| Q47292306 | A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection |
| Q35008036 | A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation |
| Q90198666 | A potential role of neutrophil extracellular traps (NETs) in kidney acute antibody mediated rejection |
| Q52939658 | A refractory case of subclinical antibody-mediated rejection due to anti-HLA-DQ antibody in a kidney transplant patient. |
| Q42280145 | Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q38206175 | Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options |
| Q38392458 | Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management |
| Q52401610 | Antibody-mediated rejection: New approaches in prevention and management. |
| Q37029874 | B cells in transplantation |
| Q38282840 | Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection |
| Q27009997 | Biologics in renal transplantation |
| Q50996014 | Bortezomib in ABO-incompatible kidney transplant desensitization: a case report. |
| Q39018530 | Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: A multicenter Midwest Pediatric Nephrology Consortium study |
| Q41495990 | Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection |
| Q38977574 | Cell-mediated and humoral acute vascular rejection and graft loss: A registry study. |
| Q39009557 | Chronic allograft injury: Mechanisms and potential treatment targets |
| Q40967497 | Chronic rejection: Differences and similarities in various solid organ transplants |
| Q38035660 | Chronic renal allograft injury: early detection, accurate diagnosis and management. |
| Q93188012 | Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients |
| Q36752176 | Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection |
| Q30279164 | Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells |
| Q39265221 | Donor-Specific Antibodies in Kidney Transplant Recipients |
| Q58805821 | Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians |
| Q47362322 | Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation |
| Q89746966 | Evaluation and Treatment of Acute Rejection in Kidney Allografts |
| Q50852390 | Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient. |
| Q89472835 | HLA in transplantation |
| Q38022711 | Identification and therapeutic management of highly sensitized patients undergoing renal transplantation. |
| Q37660263 | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy |
| Q35332072 | Interlaboratory Comparison of the Results of Lifecodes LSA Class I and Class II Single Antigen Kits for Human Leukocyte Antigen Antibody Detection |
| Q94355534 | Interventions for treating antibody‐mediated acute rejection in kidney transplant recipients |
| Q33409582 | Luminex(®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion |
| Q37361071 | Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study. |
| Q47876027 | Morphologic patterns and treatment of transplant glomerulopathy: A retrospective analysis |
| Q53610974 | Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition. |
| Q38102315 | New perspectives of immunosuppression. |
| Q38176005 | Novel immunosuppressive agents in kidney transplantation |
| Q38102662 | Pathophysiology and treatment options of chronic renal allograft damage |
| Q56956569 | Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors |
| Q36173541 | Rational clinical trial design for antibody mediated renal allograft injury. |
| Q40461706 | Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection. |
| Q40958100 | Successful treatment of severe acute antibody-mediated rejection of renal allografts with bortezomib--a report of two pediatric cases |
| Q47737016 | Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. |
| Q38068534 | Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? |
| Q89782890 | The Preliminary Results of Bortezomib Used as A Primary Treatment for An Early Acute Antibody-Mediated Rejection after Kidney Transplantation-A Single-Center Case Series |
| Q30248842 | The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. |
| Q92899718 | The therapeutic challenge of late antibody-mediated kidney allograft rejection |
| Q36102133 | Tolerogenic therapies in transplantation. |
| Q91819183 | Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study |
| Q41967328 | Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step |
| Q53135056 | [Caracterization of HLA allo-immunization and clinical impact in transfusion and organ transplantation]. |